Patient Dosing with MT-302 initiated in Ph 1 Study for Advanced or Metastatic Epithelial Tumors
“Initiation of patient dosing with MT-302 is a major milestone for Myeloid in our effort to deliver better treatment options for patients living with solid tumors. We are leading the way with our proprietary approach to in vivo programming, including with many novel CAR constructs designed for selective expression in a wide range of immune cells,” said Daniel Getts, Ph.D., CEO of Myeloid. “By advancing MT-302 into the clinic, we are harnessing the power of the innate immune system to overcome many observed limitations of CAR-Ts for solid tumors. We look forward to advancing MT-302 in our Phase 1 study and demonstrating the potential of our innate immunity platform to program cells directly in vivo and drive better outcomes.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data